These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 15951264)
1. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]. Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264 [TBL] [Abstract][Full Text] [Related]
2. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375 [TBL] [Abstract][Full Text] [Related]
3. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia]. Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279 [TBL] [Abstract][Full Text] [Related]
4. [Treatment of idiopathic hypereosinophilic syndrome with imatinib]. Sørensen AL; Larsen H Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461 [TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate for the treatment of hypereosinophilic syndromes. Antoniu SA Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585 [TBL] [Abstract][Full Text] [Related]
7. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. Menif S; Ben Romdhane N; Hafsia R Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706 [TBL] [Abstract][Full Text] [Related]
9. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467 [TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698 [TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome. Payne SM; Kovacs MJ Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212 [TBL] [Abstract][Full Text] [Related]
12. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562 [TBL] [Abstract][Full Text] [Related]
13. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib]. Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284 [TBL] [Abstract][Full Text] [Related]
15. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement. Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119 [TBL] [Abstract][Full Text] [Related]
16. Imatinib: new indication. New indications, but not robust evidence. Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899 [TBL] [Abstract][Full Text] [Related]
17. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Lierman E; Cools J Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433 [TBL] [Abstract][Full Text] [Related]
18. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Score J; Curtis C; Waghorn K; Stalder M; Jotterand M; Grand FH; Cross NC Leukemia; 2006 May; 20(5):827-32. PubMed ID: 16498388 [TBL] [Abstract][Full Text] [Related]
20. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome]. Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]